poisar

Stocks · News reference

Pentair Affirms FY2026 Adj EPS Guidance of $4.60-$4.80 vs $4.88 Est; Affirms FY2026 Sales Guidance of $3.884B-$4.009B vs $4.012B Est

Jul 28, 2026, 10:55 AMBenzinga Newsdesk

Pentair (NYSE:PNR) affirms FY2026 Adj EPS guidance from $4.60-$4.80 to $4.60-$4.80 vs $4.88 analyst estimate. Affirms FY2026 sales outlook from $3.884 billion-$4.009 billion to $3.884 billion-$4.009 billion vs $4.012

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PNR
Source
benzinga
Observed
Jul 28, 2026, 10:55 AM
Checked
Jul 28, 2026, 10:55 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 26, 2026, 1:45 PMKaplan Fox & Kilsheimer Llp

    Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 for a Leadership Role

    Kaplan Fox & Kilsheimer LLP has filed class action lawsuits against Capricor Therapeutics, Pentair plc, and Bloom Energy Corporation on behalf of investors who suffered losses. The primary case involves Capricor, where the FDA released briefing documents revealing that the company made undisclosed changes to its statistical analysis plan for a drug application, resulting in a 64% stock price drop on July 27, 2026.

    Read original at globenewswire-inc
    CAPRPNRBE